Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Phase 4

Completed

Conditions: Cataracts

Interventions: Drug: Moxifloxacin
Drug: besifloxacin

First Posted Date: 2011-02-15

Last Posted Date: 2020-12-22

Lead Sponsor: Frank A. Bucci, Jr., M.D.

Target Recruit Count: 120

Registration Number: NCT01296191

Locations: 🇺🇸
Bucci Laser Vision Institute, Wilkes-Barre, Pennsylvania, United States

TMC207TBC1003 - A Study in Healthy Volunteers Investigating the Effect of Single-dose TMC207 on the QT/QTc Interval Under Fed Conditions

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: TMC207
Drug: TMC207 placebo
Drug: Moxifloxacin placebo
Drug: Moxifloxacin

First Posted Date: 2011-02-08

Last Posted Date: 2012-11-06

Lead Sponsor: Tibotec BVBA

Target Recruit Count: 88

Registration Number: NCT01291563

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Placebo Infusion
Drug: NXL104
Drug: Moxifloxacin
Drug: Ceftaroline
Drug: Ceftazidime

First Posted Date: 2011-02-07

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT01290900

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tigecycline
Drug: placebo
Drug: moxifloxacin
Drug: 100 mL 0.9% Sodium Chloride intravenous

First Posted Date: 2011-02-01

Last Posted Date: 2011-05-24

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01287793

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

TMC435-TiDP16-C117: The Effect of TMC435 on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: TMC435
Drug: Placebo for TMC435
Drug: Placebo for moxifloxacin
Drug: Moxifloxacin

First Posted Date: 2011-01-04

Last Posted Date: 2013-05-06

Lead Sponsor: Tibotec Pharmaceuticals, Ireland

Target Recruit Count: 60

Registration Number: NCT01269294

The Optimization of Mycoplasm Pneumonia Antibiotic Therapy

Not Applicable

Completed

Conditions: Mycoplasma Pneumonia

Interventions: Drug: Cephalosporins and azithromycin
Drug: Moxifloxacin

First Posted Date: 2010-12-14

Last Posted Date: 2015-07-28

Lead Sponsor: Capital Medical University

Target Recruit Count: 208

Registration Number: NCT01259141

Locations: 🇨🇳
Capital Medical University affiliated Beijing Chaoyang Hospital, Beijing Respiratory Medicine Insititute, Beijing, Beijing, China

A Study of the Effect of ASP1941 on Cardiac Repolarization in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Cardiac Repolarization

Interventions: Drug: Placebo
Drug: ASP1941
Drug: Moxifloxacin

First Posted Date: 2010-11-02

Last Posted Date: 2011-02-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 88

Registration Number: NCT01232413

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

Phase 1

Completed

Conditions: Chronic Obstructive Pulmonary Disease
Lung Disease

Interventions: Drug: AZD3199
Drug: Moxifloxacin
Other: Placebo comparator

First Posted Date: 2010-10-18

Last Posted Date: 2011-02-16

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT01222442

Locations: 🇬🇧
Research Site, London, UK, United Kingdom

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: TMC207
Drug: Pyrazinamide
Drug: PA-824
Drug: Rifafour
Drug: Moxifloxacin

First Posted Date: 2010-10-07

Last Posted Date: 2017-02-28

Lead Sponsor: Global Alliance for TB Drug Development

Target Recruit Count: 85

Registration Number: NCT01215851

Locations: 🇿🇦
Centre for Tuberculosis Research Innovation, UCT Lung Institute, Cape Town, South Africa
🇿🇦
Task Applied Science, Karl Bremer Hospital, Cape Town, South Africa

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Placebo
Drug: mirabegron
Drug: moxifloxacin

First Posted Date: 2010-09-13

Last Posted Date: 2013-07-03

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 352

Registration Number: NCT01199523

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy